Spectrum Pharmaceuticals, Inc.
NOVEL QUINAZOLINE EGFR INHIBITORS

Abstract:

This document discloses a novel class of quinazoline EGFR inhibitors. Also disclosed are pharmaceutical compositions thereof and method for treating cancers. Disclosed herein is a novel class of quinazoline compounds which selectively and effectively inhibit the growth of cancer cells induced by the overexpression of an epidermal growth factor receptor (EGFR).